Shanghai Henlius Biotech, Inc. (HKG:2696)
69.55
-2.40 (-3.34%)
Feb 13, 2026, 3:05 PM HKT
Shanghai Henlius Biotech Revenue
Shanghai Henlius Biotech had revenue of 2.82B CNY in the half year ending June 30, 2025, with 12.76% growth. This brings the company's revenue in the last twelve months to 5.80B, up 2.79% year-over-year. In the year 2024, Shanghai Henlius Biotech had annual revenue of 5.72B with 6.11% growth.
Revenue (ttm)
5.80B CNY
Revenue Growth
+2.79%
P/S Ratio
6.16
Revenue / Employee
1.64M CNY
Employees
3,537
Market Cap
39.10B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.72B | 329.54M | 6.11% |
| Dec 31, 2023 | 5.39B | 2.18B | 67.82% |
| Dec 31, 2022 | 3.21B | 1.53B | 91.07% |
| Dec 31, 2021 | 1.68B | 1.09B | 186.34% |
| Dec 31, 2020 | 587.59M | 496.66M | 546.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 9.94B |
| Genscript Biotech | 6.50B |
| Shanghai Junshi Biosciences | 2.71B |
| RemeGen | 2.43B |
| Duality Biotherapeutics | 2.38B |
| InnoCare Pharma | 1.56B |
| Biocytogen Pharmaceuticals (Beijing) | 1.30B |
| Ascentage Pharma Group International | 428.02M |